These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 29361493)

  • 1. Many Faces of Fabry's Cardiomyopathy.
    Jain R; Kalvin L; Johnson B; Muthukumar L; Khandheria BK; Tajik AJ
    JACC Cardiovasc Imaging; 2018 Apr; 11(4):644-647. PubMed ID: 29361493
    [No Abstract]   [Full Text] [Related]  

  • 2. The electrocardiogram as a diagnostic tool for hypertrophic cardiomyopathy: revisited.
    Maron BJ
    Ann Noninvasive Electrocardiol; 2001 Oct; 6(4):277-9. PubMed ID: 11686906
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
    Morrissey RP; Philip KJ; Schwarz ER
    Cardiovasc J Afr; 2011; 22(1):38-44. PubMed ID: 21298206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late-onset Fabry disease: the cardiac sequela.
    Tremblay J; Kim S; Philbin E; Beers K; Lightle A; Belov D
    BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35680278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare presentation of Fabry disease as 'burnt-out' hypertrophic cardiomyopathy.
    Williams S; El-Medany A; Nightingale A; Ismail Y
    BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plot thickens: the progression of left ventricular 'hypertrophy' in Fabry disease.
    Geenty P; Thomas L
    Heart; 2024 Aug; 110(17):1063-1064. PubMed ID: 39043468
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal.
    Del Franco A; Iannaccone G; Meucci MC; Lillo R; Cappelli F; Zocchi C; Pieroni M; Graziani F; Olivotto I
    Heart Fail Rev; 2024 Mar; 29(2):431-444. PubMed ID: 38006470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular hypertrophy. Is there only hypertrophic cardiomyopathy?
    Lluch-Requerey C; Montilla-Garrido MA; Morgado-García-Polavieja JI; Gragera-Martínez Á; Gómez-Menchero A
    Arch Cardiol Mex; 2024; 94(1):123-126. PubMed ID: 38507316
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiology: hypertrophic cardiomyopathy.
    ; Firth J
    Clin Med (Lond); 2019 Jan; 19(1):61-63. PubMed ID: 30651247
    [No Abstract]   [Full Text] [Related]  

  • 10. Alpha galactosidase A activity in Parkinson's disease.
    Alcalay RN; Wolf P; Levy OA; Kang UJ; Waters C; Fahn S; Ford B; Kuo SH; Vanegas N; Shah H; Liong C; Narayan S; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Oliva P; Keutzer J; Marder K; Zhang XK
    Neurobiol Dis; 2018 Apr; 112():85-90. PubMed ID: 29369793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Influence of Patient-Reported Joint Manifestations on Quality of Life in Fabry Patients.
    Ivleva A; Weith E; Mehta A; Hughes DA
    JIMD Rep; 2018; 41():37-45. PubMed ID: 29380258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion.
    Lenders M; Schmitz B; Brand SM; Foell D; Brand E
    J Allergy Clin Immunol; 2018 Jun; 141(6):2289-2292.e7. PubMed ID: 29421273
    [No Abstract]   [Full Text] [Related]  

  • 13. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
    Arends M; Biegstraaten M; Wanner C; Sirrs S; Mehta A; Elliott PM; Oder D; Watkinson OT; Bichet DG; Khan A; Iwanochko M; Vaz FM; van Kuilenburg ABP; West ML; Hughes DA; Hollak CEM
    J Med Genet; 2018 May; 55(5):351-358. PubMed ID: 29437868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of left atrial size and function in hypertrophic cardiomyopathy and in Fabry disease with left ventricular hypertrophy.
    Saccheri MC; Cianciulli TF; Challapa Licidio W; Lax JA; Beck MA; Morita LA; Gagliardi JA;
    Echocardiography; 2018 May; 35(5):643-650. PubMed ID: 29457264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive pathway development for Fabry disease: a clinical approach.
    Schuller Y; Arends M; Körver S; Langeveld M; Hollak CEM
    Drug Discov Today; 2018 Jun; 23(6):1251-1257. PubMed ID: 29455022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy.
    Müntze J; Salinger T; Gensler D; Wanner C; Nordbeck P
    Eur Heart J; 2018 May; 39(20):1861-1862. PubMed ID: 29452394
    [No Abstract]   [Full Text] [Related]  

  • 17. A predominant cardiac phenotype of Anderson-Fabry disease in presence of a MYBPC3 gene mutation and a LAMA4 gene mutation.
    Laenens D; Koopman P; Cools T
    Acta Cardiol; 2019 Feb; 74(1):84-85. PubMed ID: 29415625
    [No Abstract]   [Full Text] [Related]  

  • 18. Fabry disease revisited: Management and treatment recommendations for adult patients.
    Ortiz A; Germain DP; Desnick RJ; Politei J; Mauer M; Burlina A; Eng C; Hopkin RJ; Laney D; Linhart A; Waldek S; Wallace E; Weidemann F; Wilcox WR
    Mol Genet Metab; 2018 Apr; 123(4):416-427. PubMed ID: 29530533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter regarding Morsbach et al. "Quantitative comparison of 2D and 3D late gadolinium enhancement MR imaging in patients with Fabry disease and hypertrophic cardiomyopathy".
    Ma H; Wang Y; Wang Y; Shi L; Zhang J; Wen Z; Chen L; Wang Z; Shi Y; Sun C; Pan Y; Liu J; Xie H; Yang J
    Int J Cardiol; 2018 Apr; 256():35. PubMed ID: 29395363
    [No Abstract]   [Full Text] [Related]  

  • 20. Fabry disease in cardiology practice: Literature review and expert point of view.
    Hagège A; Réant P; Habib G; Damy T; Barone-Rochette G; Soulat G; Donal E; Germain DP
    Arch Cardiovasc Dis; 2019 Apr; 112(4):278-287. PubMed ID: 30826269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.